: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT), in combination with magnetic resonance imaging (MRI), may enhance the diagnosis and staging of prostate cancer. Image fusion of separately acquired PET/CT and MRI images serve to facilitate clinical integration and treatment planning. This study aimed to investigate different PSMA PET/CT and MRI image fusion workflows for prostate cancer visualisation. : Eighteen patients with prostate cancer who underwent PSMA PET/CT and MRI prior to radical prostatectomy were retrospectively selected. Alignment of the prostate was performed between PET/CT and MRI via three techniques: semi-automatic rigid, automatic rigid, and automatic non-rigid. Image fusion accuracy was evaluated through boundary and volume agreement, quantified by the Dice Similarity Coefficient (DSC), 95% Hausdorff Distance (HD), and Mean Surface Distance (MSD), with comparison against reconstructed histopathology slices. : Image fusion using all techniques resulted in clear lesion visualisation from PSMA PET/CT overlay and anatomical detail afforded by the MRI base and was consistent with histopathology tumour location. Image fusion accuracy was within the recommended range based on a DSC of 0.8-0.9. The automatic non-rigid registration method had the highest volume agreement (DSC: 0.96 ± <0.01) and boundary agreement (HD: 1.17 ± 0.35 mm) when compared to automatic rigid (DSC 0.88 ± 0.02, HD 3.18 ± 0.29 mm) and semi-automatic rigid (DSC 0.80 ± 0.06, HD 5.25 ± 1.68 mm). : Image fusion of clinically obtained PET/CT and MRI is feasible and clinically acceptable for use in prostate cancer diagnosis and surgical management. While the best accuracy was observed with the automatic non-rigid technique, which requires further validation, image fusion with clinically accessible methods (semi-automatic rigid) may currently aid patient education, pre-operative planning, and intra-operative guidance.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11642359PMC
http://dx.doi.org/10.3390/jcm13237384DOI Listing

Publication Analysis

Top Keywords

psma pet/ct
20
pet/ct mri
20
image fusion
20
prostate cancer
16
rigid automatic
8
automatic non-rigid
8
fusion accuracy
8
volume agreement
8
pet/ct
7
mri
7

Similar Publications

Background: To examine the feasibility and safety of the SENSEI drop-in gamma probe for robot-assisted, prostate-specific membrane antigen (PSMA)-radioguided salvage surgery (RGS) in lymph node or local oligorecurrent prostate cancer (PCa), detected via PSMA positron emission tomography/computed tomography (PET/CT).

Methods: The first thirteen patients with pelvic oligorecurrent PCa who underwent [Tc]Tc-PSMA-I&S RGS using the SENSEI drop-in gamma probe at the Martini-Klinik (February-June 2024) were retrospectively analyzed. Radioactivity measurements in counts per second (CPS) as absolute values or ratios (CPS of tumor specimens/mean CPS from the patients' benign tissues) were correlated with preoperative imaging and pathological findings (benign/malignant, lesion size).

View Article and Find Full Text PDF

Here, we describe the case of a 74-year-old male patient with a high-risk prostate carcinoma who underwent positron-emission tomography/computed tomography (PET/CT) with [Ga]Ga-prostate-specific membrane antigen ([Ga]Ga-PSMA-11) for staging. [Ga]Ga-PSMA-11 PET/CT detected an extensive area of increased tracer uptake at the prostatic level, involving both lobes. Additionally, a rounded lesion approximately 4 cm in diameter was identified in the celiac region adjacent to the stomach, exhibiting moderate tracer uptake.

View Article and Find Full Text PDF

Staging of prostate Cancer with ultra-fast PSMA-PET scans enhanced by AI.

Eur J Nucl Med Mol Imaging

January 2025

Department of Nuclear Medicine and German Cancer Consortium (DKTK), University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, Essen, 45147, Germany.

Purpose: PSMA-PET is a reference standard examination for patients with prostate cancer, but even using recently introduced digital PET detectors image acquisition with standard field-of-view scanners is still in the range of 20 min. This may cause limited access to examination slots because of the growing demand for PSMA-PET. Ultra-fast PSMA-PET may enhance throughput but comes at the cost of poor image quality.

View Article and Find Full Text PDF

Recommendations from Imaging, Oncology, and Radiology Organizations to Guide Management in Prostate Cancer: Summary of Current Recommendations.

Radiol Imaging Cancer

January 2025

From Case Western Reserve University School of Medicine, Cleveland, Ohio (A.M.); University of Pittsburgh School of Medicine, Pittsburgh, Pa (E.C.); and Department of Radiology, University Hospitals, 11000 Euclid Ave, Bolwell B2600, Cleveland, OH 44115 (K.B., N.R., S.H.T.).

Prostate cancer is the second most common malignancy among male individuals in the United States and requires careful imaging approaches because of its varied presentations. This review examines prostate cancer imaging guidelines from leading organizations, including the American College of Radiology, American Urological Association, European Association of Urology, American Society of Clinical Oncology, and National Comprehensive Cancer Network, and serves as a reference highlighting commonalities and divergences in current imaging recommendations across prostate cancer states. We outline these organizations and their methods, focusing on their approaches to panel expertise, guideline development, evidence grading, and revision schedules.

View Article and Find Full Text PDF

Time-efficient HPLC Validation Methodology for the Qualitative Analysis of 68Ga PSMA-11 in Routine Clinical Usage under Isocratic Method.

Indian J Nucl Med

November 2024

Department of Nuclear Medicine and Molecular Imaging, Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India.

Background: Prostate-specific membrane antigen (PSMA) has shown to be a promising agent for prostate cancer imaging under PET-CT. With the automation in radiolabeling with 68Ga, using iTG 68Ge/68Ga generator, it has helped introduce various new diagnostic agents and achieve good manufacturing practices (GMP) simultaneously. However, before any radiopharmaceutical is put into clinical usage, it should always be checked for its radiochemical purity and other quality parameters before injecting in the patient.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!